Aficamten - Cytokinetics
Alternative Names: CK 3773274; CK-274Latest Information Update: 25 May 2025
At a glance
- Originator Cytokinetics
- Developer Corxel Pharmaceuticals; Cytokinetics
- Class Amides; Cardiovascular therapies; Heart failure therapies; Indenes; Oxadiazoles; Pyrazoles; Small molecules
- Mechanism of Action Cardiac myosin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Hypertrophic cardiomyopathy
Most Recent Events
- 13 May 2025 Adverse events and efficacy data from phase III MAPLE-HCM trial in Hypertrophic cardiomyopathy released by Cytokinetics
- 01 May 2025 FDA assigns PDUFA action date of (26/12/2025) for Aficamten for hypertrophic cardiomyopathy
- 01 May 2025 US FDA requests Risk Evaluation and Mitigation Strategy (REMS) of aficamten for Hypertrophic cardiomyopathy